Novartis Consumer Health
Action And Clinical Pharmacology: Glysennid is a laxative which selectively stimulates the colon 8 to 12 hours after ingestion. Therefore, if Glysennid is taken before retiring, sleep is usually not disturbed.
Indications And Clinical Uses: Atonic constipation (e.g., in the elderly, after surgery, in the puerperium or due to neurological disorders).
Contra-Indications: Known hypersensitivity to sennosides or any of the ingredients; appendicitis, intestinal hemorrhage, spastic constipation, intestinal obstruction, ulcerative colitis and abdominal pain or of other acute undiagnosed pathological abdominal conditions; electrolyte imbalance (i.e., hypokalemia); during lactation.
Precautions: Frequent or continued use of the preparation may lead to dependence on laxatives. The lowest effective dosage for the re-establishment of normal bowel function should be employed. Use of Glysennid requires supervision by a physician in the following conditions: use exceeding 1 week; after abdominal surgery; in children below 6 years of age; during pregnancy.
Glysennid should be kept out of the reach of children.
Adverse Reactions: Abdominal colic, diarrhea, irritation of the intestinal mucosa and loss of electrolytes may occur, particularly due to overdosage; discoloration of urine.
Symptoms And Treatment Of Overdose: Symptoms: Mainly those related to excessive catharsis: purging, griping abdominal pain, possible blood in the stool, electrolyte disturbances, excessive loss of water, nausea, diarrhea, irritation of the gastrointestinal tract and circulatory collapse.
Treatment: Gastric lavage. Careful observation and recording of vital signs. Relief of griping abdominal pain with antispasmodics. Monitoring of the cardiovascular system as well as the fluid and electrolyte balance. General supportive therapy with i.v. fluid administration for prevention and treatment of circulatory collapse.
Dosage: Adults, 17.2 to 24 mg with fluids before retiring. Children, 6 to 12 years, 8.6 to 12 mg with fluids before retiring; under 6 years, as prescribed.
Availability And Storage: 8.6 mg: Each white coated tablet contains: senna glycosides 8.6 mg derived from purified senna extract 14.33 mg (sennosides USP). Also contains cornstarch and lactose. Energy: 1.42 kJ (0.34 kcal). Sodium: trace. Bottles of 100.
12 mg: Each pink coated tablet contains: senna glycosides 12 mg derived from purified senna extract 20 mg (sennosides USP). Also contains cornstarch, lactose and tartrazine. Energy: 1.51 kJ (0.36 kcal). Sodium: trace. Bottles of 100.
GLYSENNID® Novartis Consumer Health Sennosides Laxative